Wrong skincare/makeup : Additionally, using comedogenic skincare or makeup products can also lead to bumps and inflammation
The journey through the pharmacological landscapes of a GLP-1 receptor agonist and an SSRI has revealed not only the promise they hold for improving patient outcomes but also the caution required in their concurrent administration
Cukierman-Yaffe, T., et al
doi: 10.1021/jm9909645 10 GlaesnerWVickAMMillicanREllisBTschangSHTianYet al
Hoogwerf is a former employee and minor stockholder of Eli Lilly who market the GLP-1 RA, dulaglutide, the dual agonist, tirzepatide, and the triagonist, retatrutide
After deduplication, abstracts/titles and full-texts were assessed for inclusion